IL23A and psoriasis: <h4>Background</h4>Tildrakizumab, an anti-IL-23p19 monoclonal antibody, has demonstrated efficacy in clinical trials, but real-world evidence remains crucial for confirming its profile in diverse populations.<h4>Methods</h4>We have conducted a multicenter, retrospective observational study within the Spanish Psoriasis Group (GPS).